Science to practice: will randomized prospective clinical trials be necessary for RF ablation of large liver tumors with liposomal doxorubicin?
Unger
Evan C
EC
Department of Radiology University of Arizona 1501 N. Campbell Ave. Tucson, AZ 85724, USA. eunger@radiology.arizona.edu
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000111:Acetylcysteine / Q000494:pharmacology; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis; D053148:Caspase 3 / Q000378:metabolism; D017115:Catheter Ablation; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004249:DNA Damage; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery*; D018384:Oxidative Stress; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014443:Tyrosine / Q000031:analogs & derivatives / Q000378:metabolism
D000447:Aldehydes; D000903:Antibiotics, Antineoplastic; D018840:HSP70 Heat-Shock Proteins; D006657:Histones; C002744:3-nitrotyrosine; D014443:Tyrosine; D004317:Doxorubicin; D000080242:8-Hydroxy-2'-Deoxyguanosine; D053148:Caspase 3; D003849:Deoxyguanosine; C027576:4-hydroxy-2-nonenal; D000111:Acetylcysteine